Debu Tripathy
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Cancer survivorship and care
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 247
- HER2/EGFR in Cancer Research 98
- Cancer Treatment and Pharmacology 79
- Lung Cancer Research Studies 22
- Cancer Cells and Metastasis 21
-
- Advanced Breast Cancer Therapies 113
- Co-authors
- Dennis J. Slamon (11 shared papers)Melody Cobleigh (17 shared papers)Charles L. Vogel (7 shared papers)Louis Fehrenbacher (6 shared papers)Steven Shak (7 shared papers)Virginia Paton (3 shared papers)Nicholas J. Robert (3 shared papers)Janet Wolter (2 shared papers)
- Journals
- Journal of Clinical Oncology (83 papers)Cancer Research (68 papers)Annals of Oncology (25 papers)Breast Cancer Research and Treatment (24 papers)Clinical Cancer Research (11 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Debu Tripathy
399 papers receiving 15.8k citations
Debu Tripathy's Hit Papers
Peers
Comparison fields: 5 of 158
- Oncology 8.7k
- Cancer Research 2.3k
- Radiology, Nuclear Medicine and Imaging 3.2k
- Pulmonary and Respiratory Medicine 3.0k
- Anesthesiology and Pain Medicine 482
Countries citing papers authored by Debu Tripathy
This map shows the geographic impact of Debu Tripathy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debu Tripathy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debu Tripathy more than expected).
Fields of papers citing papers by Debu Tripathy
This network shows the impact of papers produced by Debu Tripathy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debu Tripathy. The network helps show where Debu Tripathy may publish in the future.
Co-authors
The 25 scholars most cited alongside Debu Tripathy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 425 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Hit paper breakdown → | 1999 | 2174 |
| 2 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Hit paper breakdown → | 2002 | 1509 |
| 3 | Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Hit paper breakdown → | 1996 | 1089 |
| 4 | Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Hit paper breakdown → | 1998 | 848 |
| 5 | Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer Hit paper breakdown → | 2019 | 616 |
| 6 | Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment Hit paper breakdown → | 2017 | 530 |
| 7 | 2011 | 286 | |
| 8 | 2018 | 278 | |
| 9 | Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. | 1999 | 229 |
| 10 | 2004 | 229 | |
| 11 | 2017 | 224 | |
| 12 | 2004 | 221 | |
| 13 | 2018 | 211 | |
| 14 | 2014 | 196 | |
| 15 | 2004 | 192 | |
| 16 | 2017 | 184 | |
| 17 | 2001 | 183 | |
| 18 | 2004 | 173 | |
| 19 | 2001 | 145 | |
| 20 | 2001 | 145 |
About Debu Tripathy
Debu Tripathy is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 425 papers that have together received 16.2k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (113 papers), HER2/EGFR in Cancer Research (98 papers), Breast Cancer Treatment Studies (84 papers), Cancer Treatment and Pharmacology (79 papers), Cancer Genomics and Diagnostics (25 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Lung Cancer Research Studies (22 papers) and Cancer Cells and Metastasis (21 papers). The work is most often cited by research in Oncology (8.7k citations), Cancer Research (2.3k citations), Radiology, Nuclear Medicine and Imaging (3.2k citations), Pulmonary and Respiratory Medicine (3.0k citations) and Anesthesiology and Pain Medicine (482 citations). Debu Tripathy has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Dennis J. Slamon, Melody Cobleigh, Charles L. Vogel, Louis Fehrenbacher, Steven Shak, Virginia Paton, Nicholas J. Robert, Janet Wolter, Suzy Scholl and José Baselga. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.